These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1165 related articles for article (PubMed ID: 11978147)
1. Lipid-lowering drug use and cardiovascular events after myocardial infarction. Klungel OH; Heckbert SR; de Boer A; Leufkens HG; Sullivan SD; Fishman PA; Veenstra DL; Psaty BM Ann Pharmacother; 2002 May; 36(5):751-7. PubMed ID: 11978147 [TBL] [Abstract][Full Text] [Related]
2. Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. Silverman MG; Ference BA; Im K; Wiviott SD; Giugliano RP; Grundy SM; Braunwald E; Sabatine MS JAMA; 2016 Sep; 316(12):1289-97. PubMed ID: 27673306 [TBL] [Abstract][Full Text] [Related]
3. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting. Cziraky MJ; Watson KE; Talbert RL J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279 [TBL] [Abstract][Full Text] [Related]
4. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study. Hague W; Forder P; Simes J; Hunt D; Tonkin A; Am Heart J; 2003 Apr; 145(4):643-51. PubMed ID: 12679760 [TBL] [Abstract][Full Text] [Related]
5. Drug treatment of hyperlipidemia in women. Walsh JM; Pignone M JAMA; 2004 May; 291(18):2243-52. PubMed ID: 15138247 [TBL] [Abstract][Full Text] [Related]
6. Benefits of intensive lipid-lowering therapies in patients with acute coronary syndrome: a systematic review and meta-analysis. Wu XD; Ye XY; Liu XY; Lin Y; Lin X; Li YY; Ye BH; Sun JC Ann Med; 2024 Dec; 56(1):2389470. PubMed ID: 39126262 [TBL] [Abstract][Full Text] [Related]
7. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA; 2002 Dec; 288(23):2998-3007. PubMed ID: 12479764 [TBL] [Abstract][Full Text] [Related]
11. Lipid-lowering for prevention of coronary heart disease: what policy now? Ul Haq I; Ramsay LE; Pickin DM; Yeo WW; Jackson PR; Payne JN Clin Sci (Lond); 1996 Oct; 91(4):399-413. PubMed ID: 8983865 [TBL] [Abstract][Full Text] [Related]
12. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial. Hunt D; Young P; Simes J; Hague W; Mann S; Owensby D; Lane G; Tonkin A Ann Intern Med; 2001 May; 134(10):931-40. PubMed ID: 11352694 [TBL] [Abstract][Full Text] [Related]
13. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial. Murphy SA; Cannon CP; Wiviott SD; McCabe CH; Braunwald E J Am Coll Cardiol; 2009 Dec; 54(25):2358-62. PubMed ID: 20082923 [TBL] [Abstract][Full Text] [Related]
14. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. LIPID Study Group (Long-term Intervention with Pravastatin in Ischaemic Disease) Lancet; 2002 Apr; 359(9315):1379-87. PubMed ID: 11978335 [TBL] [Abstract][Full Text] [Related]
15. Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy. Isles CG; Paterson JR QJM; 2000 Sep; 93(9):567-74. PubMed ID: 10984551 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of long-term ezetimibe/simvastatin treatment in patients with familial hypercholesterolemia. Avellone G; Di Garbo V; Guarnotta V; Scaglione R; Parrinello G; Purpura L; Torres D; Campisi D Int Angiol; 2010 Dec; 29(6):514-24. PubMed ID: 21173733 [TBL] [Abstract][Full Text] [Related]
17. Rationale, design features, and baseline characteristics: The Heart Institute of Japan-PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ-PROPER). Kawada-Watanabe E; Ogawa H; Koyanagi R; Arashi H; Yamaguchi J; Matsui K; Hagiwara N J Cardiol; 2017 Mar; 69(3):536-541. PubMed ID: 27349705 [TBL] [Abstract][Full Text] [Related]
18. Statins and secondary prevention of coronary heart disease. Ahmed M; Griffiths P Br J Community Nurs; 2004 Apr; 9(4):160-5. PubMed ID: 15150487 [TBL] [Abstract][Full Text] [Related]
19. Lipid-lowering effect of preoperative statin therapy on postoperative major adverse cardiac events after coronary artery bypass surgery. Thielmann M; Neuhäuser M; Marr A; Jaeger BR; Wendt D; Schuetze B; Kamler M; Massoudy P; Erbel R; Jakob H J Thorac Cardiovasc Surg; 2007 Nov; 134(5):1143-9. PubMed ID: 17976441 [TBL] [Abstract][Full Text] [Related]
20. Four years' treatment efficacy of patients with severe hyperlipidemia. Lipid lowering drugs versus LDL-apheresis. Schiel R; Bambauer R; Müller UA Int J Artif Organs; 1995 Dec; 18(12):786-93. PubMed ID: 8964646 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]